Expression of gastrin and cholecystokinin B receptor in Lateolabrax maculatus [PDF]
Aquaculture and Fisheries, 2023 Gastrin (gas) is a peptide hormone that stimulates gastric acid secretion by gastric parietal cells and stimulates gastric motility. The cholecystokinin B receptor (cckbr) can act as a receptor for gastrin, conveying regulatory information on gastrin ...
Tingwen Cui +3 more
doaj +3 more sources
Cholecystokinin B receptor agonists alleviates anterograde amnesia in cholecystokinin-deficient and aged Alzheimer's disease mice [PDF]
Alzheimer’s Research & TherapyBackground As one major symptom of Alzheimer’s disease (AD), anterograde amnesia describes patients with an inability in new memory formation. The crucial role of the entorhinal cortex in forming new memories has been well established, and the ...
Nan Zhang +11 more
doaj +4 more sources
Expression of the Cholecystokinin-B Receptor in Neoplastic Gastric Cells. [PDF]
Horm Cancer, 2018 Gastric cancer is an important disease due to its high mortality. Despite the decline in frequency, most cases are discovered late in its course, and most of the cancer patients die within a few years of diagnosis. In addition to Helicobacter pylori gastritis, gastrin is considered an important factor in the development of this disease, and thus ...
Mjønes P +6 more
europepmc +8 more sources
Single-chain Fragment variable antibody targeting cholecystokinin-B receptor for pain reduction [PDF]
Neurobiology of Pain, 2021 The cholecystokinin B receptor and its neuropeptide ligand are upregulated in chronic neuropathic pain models. Single-chain Fragment variable antibodies were generated as preferred non-opioid targeting therapy blocking the cholecystokinin B receptor to ...
K.N. Westlund +7 more
doaj +2 more sources
25380 Cholecystokinin-B Receptor -Mediates Growth of Hepatocellular Carcinoma [PDF]
Journal of Clinical and Translational Science, 2021 IMPACT: Cholecystokinin-B Receptor -Mediates Growth of Hepatocellular Carcinoma with the use proglumide. Proglumide is a non-selective antagonistic drug therefore, strategies that block signaling at the CCK-BR may provide to be a novel therapeutic option
Martha Dee Gay +5 more
doaj +2 more sources
Cholecystokinin-B Receptor-Targeted Nanoparticle for Imaging and Detection of Precancerous Lesions in the Pancreas [PDF]
Biomolecules, 2021 Survival from pancreatic cancer remains extremely poor, in part because this malignancy is not diagnosed in the early stages, and precancerous pancreatic intraepithelial neoplasia (PanIN) lesions are not seen on routine radiographic imaging.
Jill P. Smith +4 more
doaj +2 more sources
Heteromerization of μ-opioid receptor and cholecystokinin B receptor through the third transmembrane domain of the μ-opioid receptor contributes to the anti-opioid effects of cholecystokinin octapeptide [PDF]
Experimental and Molecular Medicine, 2018 Pain medicine: Boosting the potency of opioid analgesics A hormone known to weaken the pain-relieving effects of opioid drugs does so because of interaction between the hormone receptor and the opioid receptor.
Yin Yang +5 more
doaj +2 more sources
Single nucleotide polymorphisms on Cholecystokinin B Receptor gene as a candidate gene for crowing in Pelung chickens. [PDF]
Journal of Advanced Veterinary and Animal ResearchObjective: This study aims to explore mutation based on single nucleotide polymorphism (SNP) in the Cholecystokinin B receptor (CCKBR) gene of Pelung chickens.
Indrawati Yudha Asmara +2 more
doaj +2 more sources
Implicating the cholecystokinin B receptor in liver stem cell oncogenesis.
Am J Physiol Gastrointest Liver PhysiolThis investigation identified a novel pathway involving the activation of hepatic stem cells and liver oncogenesis. Receptor blockade or genetic disruption of the cholecystokinin-B receptor (CCK-BR) signaling pathway decreased the activation and proliferation of hepatic stem cells after liver injury without eliminating the regenerative capacity of ...
Gay MD +8 more
europepmc +4 more sources
A cholecystokinin B receptor antagonist and cocaine interaction, phase I study. [PDF]
CNS Neurosci Ther, 2019 SummaryAimsRPR102681, a cholecystokinin‐B antagonist, increased dopamine (DA) release and reduced cocaine self‐administration in animals. This pilot study sought to assess the safety and pharmacokinetics (PK) of co‐administration ofRPR102681 and cocaine, and to confirm the DA release mechanism ofRPR102681.MethodsSixteen cocaine‐dependent participants ...
Elkashef A +12 more
europepmc +4 more sources